Guidelines for Management of Tricuspid Regurgitation at 6‑Month Follow‑Up

Follow‑up Assessment Priorities

At the 6‑month visit, a comprehensive transthoracic echocardiogram should be performed to define tricuspid regurgitation (TR) severity, right‑ventricular (RV) size and systolic function, and tricuspid annular dimensions, while also evaluating symptoms of right‑heart failure and underlying causes such as atrial fibrillation or pulmonary hypertension. 1, 2

TR severity is quantified using effective regurgitant orifice area, vena contracta width, and color‑Doppler imaging to categorize the lesion as mild, moderate, or severe. 1
RV dimensions and systolic function (including presence of dilation or dysfunction) are essential determinants for timing of any intervention. 1, 2
A tricuspid annular diameter > 40 mm (or > 21 mm/m²) signifies significant annular dilation and guides surgical decision‑making. 1
Pulmonary artery systolic pressure should be measured to identify pulmonary hypertension, which markedly influences prognosis and therapeutic strategy. 1

Screening for right‑heart‑failure signs—peripheral edema, ascites, hepatic congestion, and reduced exercise tolerance—identifies patients who may need escalation of therapy. 2
Detection of atrial fibrillation is important because it can exacerbate functional TR and warrants rhythm‑control measures or anticoagulation. 1
Assessment for cardiovascular implantable electronic device leads is required, as lead‑associated TR may be a reversible contributor. 2
Baseline liver and kidney function tests are needed to uncover end‑organ damage; irreversible liver cirrhosis is a contraindication to surgical repair. 1

Surveillance echocardiography every 6–12 months is recommended to monitor for progression. 1
Guideline‑directed medical therapy for any coexisting left‑ventricular systolic dysfunction should be optimized. 1
Loop diuretics are indicated for volume overload when present. 1
Aldosterone antagonists may be added for additional volume management in right‑sided heart failure. 1

Patients with severe, symptomatic TR should be referred promptly to a multidisciplinary Heart Team at a primary or comprehensive valve center. 2
Surgical tricuspid valve repair or replacement is advised when RV dilation or progressive RV dysfunction is evident, ideally before the onset of severe RV failure or irreversible end‑organ damage. 1, 2
In isolated severe secondary TR with symptoms or RV dilation—and in the absence of severe RV/LV dysfunction or advanced pulmonary vascular disease—isolated tricuspid valve surgery is appropriate. 1
Transcatheter tricuspid valve interventions may be considered for patients who are deemed inoperable or at high surgical risk. 1

Close monitoring for the emergence of RV dilation or systolic dysfunction is essential. 1, 2
In cases where severe TR is driven by atrial fibrillation and RV remodeling progresses despite optimal medical therapy, tricuspid valve repair can be contemplated. 1
Earlier intervention is increasingly favored to prevent irreversible RV injury and end‑organ dysfunction. 2

Referral should not be postponed until severe RV dysfunction or liver cirrhosis develop, as these conditions markedly increase surgical risk and are linked to poor outcomes. 1, 2
Concomitant left‑sided valve disease must be evaluated; when left‑sided valve surgery is required, simultaneous tricuspid valve surgery is recommended for severe TR. 1, 2

B‑type natriuretic peptide (BNP) levels aid in assessing disease severity and guiding therapeutic adjustments. 1
Cardiopulmonary exercise testing can uncover functional limitations in patients who are otherwise asymptomatic. 1
Cardiac magnetic resonance imaging provides detailed RV volume and functional data when echocardiography is suboptimal. 1
A pre‑operative tricuspid valve tethering height > 8 mm predicts recurrent TR after repair and should be measured when surgical planning is undertaken. 1